MISSISSAUGA, ON – Today, AstraZeneca announced the Canadian availability of Breztri™ Aerosphere® (budesonide / glycopyrronium / formoterol fumarate dihydrate), indicated for the long-term maintenance treatment to reduce exacerbations of chronic obstructive pulmonary… Read More
RINVOQ is now approved as the first and only oral JAK inhibitor for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) RINVOQ is the first and only JAK inhibitor approved for… Read More
Would you like to know how Vancouver Island based health researchers are transforming health care in British Columbia and around the world? We are taking Health xChange on the road again!… Read More
adMare BioInnovations is pleased to welcome Travis McCready, Head of Life Sciences, Industries Americas, at Jones Lang Lasalle (JLL), as a new member of its Board of Directors. With more… Read More
Financing Round Led by OrbiMed with participation from Lumira Ventures, Harrington Discovery Institute and existing investors Advent Life Sciences and Belinda Termeer Therapy development focused on addressing a fundamental mechanism… Read More
